Date: 2014-09-29
Type of information: Initiation of the trial
phase: preclinical
Announcement: initiation of the trial
Company: Mymetics (Switzerland)
Product: HIV vaccine candidate
Action mechanism:
Disease: HIV infection
Therapeutic area: Infectious diseases
Country: USA
Trial details:
Latest
news: * On September 29, 2014, Mymetics Corporation announced that its HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. Research to be funded by the Bill & Melinda Gates Foundation. The study will be led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program. This new study follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS) in Beijing, China in which a two-component vaccine protected all monkeys against repeated AIDS virus exposures from persistent infection. One of the vaccine components further showed a strong safety and tolerance profile in a Phase I clinical trial in human volunteers. With its HIV-1 (human immunodeficiency virus type 1) vaccine candidate, produced through its proprietary virosome technology and judicious antigen design, Mymetics aims to provide both a first line of defense through mucosal protection as well as a second line of defense against infection through the generation of blood antibodies. The new trial, to begin in October 2014, will involve 36 rhesus monkeys (n=12 per group) and compare two antigen vaccination regimens with placebo, followed by intra-vaginal challenges with live virus that carries an envelope that differs from the one in the vaccine preparation. Results are expected at the end of 2015.
